breast cancer – Page 3 – media

FDA approves first biosimilar for the treatment of certain breast and stomach cancers

The US Food and Drug Administration (FDA) today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the US for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the US for the treatment of cancer.
- Source: mdlinx
- 628
- December 5, 2017
breast cancer FDA herceptin New Approvals Ogivri stomach cancer
Are These Four Viruses Present in Breast Tissue before Breast Cancer? – Medical News Bulletin

A study examines the association between viruses and breast cancer by examining the presence of the four viruses in normal breast tissue and after cancer development.
- Source: medicalempires
- 534
- November 24, 2017
breast cancer Researches
Encouraging oxygen’s assault on iron may offer new way to kill lung cancer cells

Blocking the motion of a key protein frees oxygen to injury iron-dependent proteins in lung and breast cancer cells, slowing their enlargement and making them more straightforward to kill.
- Source: medical-newspaper
- 558
- November 24, 2017
breast cancer lung cancer Researches
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy

Novartis announced positive topline results from the global MONALEESA-7 trial, the second Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer. The MONALEESA-7 trial met its primary endpoint of progression-free survival (PFS) in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.
- Source: Novartis
- 809
- November 10, 2017
breast cancer Clinical Trials Kisqali Phase
Hormone replacement therapy may be beneficial for women’s memory

"Our study suggests that estrogen treatment after menopause protects the memory that is needed for short-term cognitive tasks from the effects of stress," said Alexandra Ycaza Herrera, the study's lead author and a researcher at the USC Leonard Davis School of Gerontology.
- Source: Medicalxpress
- 545
- November 3, 2017
breast cancer hormone menopause Researches women
New genetic variants contribute to the risk of breast cancer in women, study reveals

A new study reveals seventy-two novel genetic variants that are responsible for breast cancer risk. Published in the journals Nature and Nature Genetics, of these 72 variants, 65 are common variants that predispose patients to breast cancer and a further seven variants predispose particularly to estrogen -receptor negative breast cancer - the subcategory of cases that do not respond to hormonal treatments.
- Source: news-medical
- 479
- October 25, 2017
breast cancer Researches
Cholesterol byproduct hijacks immune cells, lets breast cancer spread

High cholesterol levels have been associated with breast cancer spreading to other sites in the body, but doctors and researchers don't know the cause for the link. A new study by University of Illinois researchers found that the culprit is a byproduct of cholesterol metabolism that acts on specific immune cells so that they facilitate the cancer's spread instead of stopping it.
- Source: Medicalxpres
- 722
- October 13, 2017
breast cancer cholesterol metabolism Researches
FDA approves new treatment for certain advanced or metastatic breast cancers

The U.S. Food and Drug Administration(FDA) approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient’s hormones (endocrine therapy).
- Source: fda.gov
- 879
- September 30, 2017
breast cancer FDA New Approvals therapy
Cynvenio Biosystems initiates breast cancer monitoring study in US

Cynvenio Biosystems has initiated a clinical study to evaluate its LiquidBiopsy ClearID test in combination with NK Score natural killer cell activity to monitor breast cancer patients in the US.
- Source: medicaldevice-network
- 561
- August 22, 2017
breast cancer Clinical Researches
EU OKs first-line use of AZ’ Faslodex

EU regulators are permitting the use of AstraZeneca’s breast cancer drug Faslodex at an earlier stage of the treatment pathway in patients with certain forms of the disease.
- Source: pharmatimes
- 765
- July 28, 2017
breast cancer EU inhibitor New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.